Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Chief Commercial Officer | March 23, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date March 23, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,654 |
Last balance in matching sequence
After 2021-03-23 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2021-03-23 · Sale · Disposed 18 · Balance 7,745 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 2 · 2021-03-23 · Sale · Disposed 74 · Balance 7,671 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 3 · 2021-03-23 · Sale · Disposed 655 · Balance 7,016 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 4 · 2021-03-23 · Sale · Disposed 268 · Balance 6,748 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 5 · 2021-03-23 · Sale · Disposed 94 · Balance 6,654 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 21,554 |
Reported balance
Holding disclosure · report date 2021-03-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 21,554 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2018 Filed Oct 26, 2018 00:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,636 | $128.66 | $210,487.60 |
DisclosureSEC source: 0001093557-18-000223 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,458 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $128.34 to $129.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 220 | $142.49 | $31,348.39 |
DisclosureSEC source: 0001093557-18-000209 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,094 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.23 to $142.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 556 | $141.76 | $78,817.00 |
DisclosureSEC source: 0001093557-18-000209 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,314 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.19 to $142.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 820 | $140.84 | $115,491.01 |
DisclosureSEC source: 0001093557-18-000209 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,870 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.14 to $141.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 80 | $139.72 | $11,177.80 |
DisclosureSEC source: 0001093557-18-000209 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,690 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $139.11 to $139.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2018 Filed Sep 27, 2018 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 60 | $138.25 | $8,294.80 |
DisclosureSEC source: 0001093557-18-000209 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,770 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $137.92 to $138.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,180 | $143.76 | $457,141.54 |
DisclosureSEC source: 0001093557-18-000200 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,804 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,303 | $143.76 | $331,068.23 |
DisclosureSEC source: 0001093557-18-000200 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,984 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 31, 2018 Filed Sep 13, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 20,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-18-000200 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,830 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F4 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 31, 2018 Filed Sep 13, 2018 01:22 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 20,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-18-000200 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,287 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F2 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $143.09 | $14,309.00 |
DisclosureSEC source: 0001093557-18-000174 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 550 | $140.52 | $77,287.27 |
DisclosureSEC source: 0001093557-18-000174 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 100 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.27 to $141.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,934 | $139.73 | $270,236.27 |
DisclosureSEC source: 0001093557-18-000174 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 650 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.24 to $140.24. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 450 | $103.30 | $46,486.98 |
DisclosureSEC source: 0001093557-18-000151 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,067 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $103.03 to $103.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,131 | $102.31 | $218,026.45 |
DisclosureSEC source: 0001093557-18-000151 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,517 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $102.03 to $103.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 00:26 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,581 | $98.58 | $254,431.11 |
DisclosureSEC source: 0001093557-18-000141 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,648 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $97.99 to $98.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 23, 2018 Filed May 25, 2018 23:52 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,581 | $86.00 | $221,962.64 |
DisclosureSEC source: 0001093557-18-000100 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,229 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.76 to $86.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 23:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,581 | $73.09 | $188,649.16 |
DisclosureSEC source: 0001093557-18-000072 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,810 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.61 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 22:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,581 | $68.44 | $176,642.61 |
DisclosureSEC source: 0001093557-18-000068 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,391 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.35 to $68.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:15 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,252 | $60.73 | $258,226.51 |
DisclosureSEC source: 0001093557-18-000063 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,429 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:15 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,835 | $60.73 | $172,171.25 |
DisclosureSEC source: 0001093557-18-000063 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,681 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:15 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,221 | $60.73 | $134,882.66 |
DisclosureSEC source: 0001093557-18-000063 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,516 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:30 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 38,502 | $0.00 | $38.50 |
DisclosureSEC source: 0001093557-18-000032 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,737 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 69,509 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,638 | $56.32 | $92,252.32 |
DisclosureSEC source: 0001093557-18-000020 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,972 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $55.80 to $56.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 00:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $54.67 | $89,383.82 |
DisclosureSEC source: 0001093557-18-000007 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,610 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.51 to $54.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $56.39 | $92,203.70 |
DisclosureSEC source: 0001093557-17-000243 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,245 F1 · price: This transaction was executed in multiple trades at prices ranging from $56.16 to $56.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 24, 2017 Filed Nov 27, 2017 22:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $55.53 | $90,787.79 |
DisclosureSEC source: 0001093557-17-000231 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 18,880 F1 · price: This transaction was executed in multiple trades at prices ranging from $55.34 to $55.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 21:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $44.82 | $73,273.51 |
DisclosureSEC source: 0001093557-17-000207 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,515 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.59 to $45.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $69.77 | $114,079.84 |
DisclosureSEC source: 0001093557-17-000205 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 22,150 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.56 to $70.17. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,184 | $71.81 | $300,467.27 |
DisclosureSEC source: 0001093557-17-000189 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,049 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,427 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:22 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000189 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,233 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,427 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 23:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,635 | $75.26 | $123,052.88 |
DisclosureSEC source: 0001093557-17-000180 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 23,785 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.99 to $75.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 22:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,187 | $78.22 | $249,272.80 |
DisclosureSEC source: 0001093557-17-000157 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 25,420 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.65 to $78.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 23, 2017 Filed May 25, 2017 23:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $68.29 | $217,290.19 |
DisclosureSEC source: 0001093557-17-000128 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,607 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.92 to $69.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $75.78 | $241,131.01 |
DisclosureSEC source: 0001093557-17-000106 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,369 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.33 to $76.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $76.38 | $243,028.75 |
DisclosureSEC source: 0001093557-17-000094 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,551 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.79 to $76.86. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:50 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,208 | $77.55 | $248,782.32 |
DisclosureSEC source: 0001093557-17-000068 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,815 F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F1 · balance_after: Included in this number are 68,676 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:50 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,527 | $77.55 | $273,520.97 |
DisclosureSEC source: 0001093557-17-000068 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,023 F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F1 · balance_after: Included in this number are 68,676 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:50 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,694 | $77.55 | $519,123.72 |
DisclosureSEC source: 0001093557-17-000068 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,550 F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F1 · balance_after: Included in this number are 68,676 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:50 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 27,510 | $0.00 | $27.51 |
DisclosureSEC source: 0001093557-17-000068 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,244 F1 · balance_after: Included in this number are 68,676 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| February 23, 2017 Filed Feb 25, 2017 00:52 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $78.42 | $249,529.58 |
DisclosureSEC source: 0001093557-17-000037 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,733 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $79.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 23, 2017 Filed Jan 26, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $79.50 | $252,977.59 |
DisclosureSEC source: 0001093557-17-000021 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,915 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $79.01 to $79.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2016 Filed Dec 29, 2016 01:12 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $62.17 | $197,831.30 |
DisclosureSEC source: 0001093557-16-000768 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 19,097 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.72 to $62.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $70.19 | $223,350.31 |
DisclosureSEC source: 0001093557-16-000754 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 22,279 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.84 to $70.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $81.12 | $258,109.52 |
DisclosureSEC source: 0001093557-16-000731 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 25,461 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.42 to $81.87. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 23, 2016 Filed Sep 28, 2016 00:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,182 | $93.97 | $298,999.81 |
DisclosureSEC source: 0001093557-16-000714 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,643 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $93.86 to $94.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,223 | $93.72 | $395,790.96 |
DisclosureSEC source: 0001093557-16-000697 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,582 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018, and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,445 | $93.72 | $416,597.40 |
DisclosureSEC source: 0001093557-16-000697 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,805 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018, and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.